Corrinne G Kulick

  • Citations Per Year
Learn More
PURPOSE To characterize the nature of a heparin contaminant's clinical effects in cases reported to the Adverse Event Reporting System (AERS). The FDA received reports of heparin-associated adverse events (AEs) starting in late 2007-early 2008 during a national investigation of allergic-type events. The investigation identified Baxter Healthcare-brand(More)
3106 Background: Tyrosine kinase inhibitors (TKIs) interfere with several critical signal transduction pathways in cancer. Nine TKIs have been FDA approved to treat a variety of malignancies. TKIs have been associated with severe liver injury (SLI). Whether this liver injury is a class effect, or specific to certain TKIs is being investigated. METHODS(More)
BACKGROUND In 2014, the U.S. Public Health Service (USPHS) Commissioned Corps deployed to Monrovia, Liberia, to operate a 25-bed Ebola treatment unit (ETU) constructed by the U.S. Military. The ETU was named the Monrovia Medical Unit (MMU) and was constructed from an U.S. Air Force Expeditionary Medical Support (EMEDS) unit with modifications on the basis(More)
BACKGROUND In pre-approval trials, there was an increased incidence of mild, transient elevations of liver aminotransferases in study subjects treated with dimethyl fumarate (DMF). OBJECTIVE/METHODS To evaluate post-marketing cases of drug-induced liver injury associated with DMF. RESULTS We identified 14 post-marketing cases of clinically significant(More)
  • 1